TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of “Moderate Buy” from Analysts
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) has received an average rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among […]
More Stories
Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) to Issue Dividend of $0.11 on September 27th
Invesco Russell 1000 Dynamic Multifactor ETF (BATS:OMFL – Get Free Report) announced a dividend on Friday, September 20th, NASDAQ reports....
Cambria Global Momentum ETF (BATS:GMOM) Raises Dividend to $0.36 Per Share
Cambria Global Momentum ETF (BATS:GMOM – Get Free Report) declared a dividend on Friday, September 20th, NASDAQ reports. Shareholders of...
Invesco Short Duration Bond ETF (ISDB) to Issue Dividend of $0.11 on September 27th
Invesco Short Duration Bond ETF (BATS:ISDB – Get Free Report) announced a dividend on Friday, September 20th, NASDAQ reports. Investors...
Sudan: UN chief alarmed at full-scale assault on El Fasher
The UN Secretary-General is gravely alarmed by reports of a full-scale assault on El Fasher by the Rapid Support Forces...
Lennar (NYSE:LEN) Issues Quarterly Earnings Results, Beats Estimates By $0.28 EPS
Lennar (NYSE:LEN – Get Free Report) posted its quarterly earnings results on Thursday. The construction company reported $3.90 earnings per...
Secret Service, Homeland Security Sued Over Records Related to Trump Assassination Attempt
By Jack Phillips A lawsuit was filed against the U.S. Secret Service and Department of Homeland Security (DHS) in a...